GlassScriptPhysician profile
Khaldoun A Debian
NPI 1932168796
$5,640.88
in general payments reported to CMS, 2019-2025
32 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $547 · 2021: $984 · 2022: $935 · 2023: $794 · 2024: $1,021 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910 · Debt Forgiveness: $80.89 · Education: $11.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.69 |
| Debt Forgiveness | $80.89 |
| Education | $11.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,195.56 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $919.48 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $746.23 | 2019-2024 | Entyvio, Gattex |
| Abbvie INC. | $650.12 | 2020-2025 | Viberzi, Linzess, Creon |
| Pfizer INC. | $300.93 | 2020-2025 | |
| Ardelyx, INC. | $255.71 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $242.38 | 2021-2023 | |
| Gilead Sciences, INC. | $226.91 | 2022-2025 | |
| Genzyme Corporation | $131.00 | 2023-2025 | |
| Redhill Biopharma INC. | $102.56 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $99.84 | 2024 | |
| Olympus America INC. | $80.89 | 2024 | Endocapsule Small Intestinal Capsule Endoscope Set |
| Qol Medical, LLC | $78.50 | 2024-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $60.84 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $56.86 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $54.63 | 2021 | |
| Ferring Pharmaceuticals INC. | $52.54 | 2021-2024 | Clenpiq, Rebyota |
| Madrigal Pharmaceuticals | $45.68 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $42.48 | 2023-2024 | Linzess |
| Celgene Corporation | $41.61 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $41.55 | 2025 | |
| Alfasigma USA, INC. | $29.57 | 2020 | |
| Allergan, INC. | $26.00 | 2019 | |
| Novo Nordisk INC | $24.94 | 2025 | Wegovy |
| Exact Sciences Corporation | $22.95 | 2023 | Cologuard Collection Kit |
| W. L. Gore & Associates, INC. | $21.25 | 2020 | |
| Evoke Pharma, INC. | $19.59 | 2022 | |
| Boston Scientific Corporation | $19.39 | 2022 | |
| Vivus LLC | $19.30 | 2024 | Qsymia |
| Grifols USA, LLC | $17.54 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.05 | 2024 | Dupixent |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaldoun Debian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.